ERYTHROMYCIN Drug Patent Profile

Which patents cover Erythromycin, and what generic alternatives are available?

Erythromycin is a drug marketed by Barr, Pharmobedient, Encube, Fougera Pharms, Padagis Us, Elkins Sinn, Bausch And Lomb, Pharmaderm, Pharmafair, Sentiss, Paddock Llc, Alpharma Us Pharms, Bausch, Lilly, Pai Holdings Pharm, Pharmobedient Cnsltg, Renaissance Pharma, Epic Pharma Llc, Amneal Pharms Co, Torrent, Abon Pharms Llc, Alembic, Alkem Labs Ltd, Cadila Pharms Ltd, Teva Pharms Usa Inc, Zydus Lifesciences, Zydus Pharms, Rising, Ivax Sub Teva Pharms, Watson Labs, Cosette, Life Labs, Amneal Pharms, Ani Pharms, Ph Health, Dista, Naska, Parke Davis, Aurobindo Pharma Usa, Abraxis Pharm, Baxter Hlthcare, Exela Pharma, Gland, Nexus, Teva Parenteral, Lederle, and Purepac Pharm. and is included in seventy-eight NDAs.

The generic ingredient in ERYTHROMYCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.

Summary for ERYTHROMYCIN

US Patents:	0
Applicants:	47
NDAs:	78
Finished Product Suppliers / Packagers:	31
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	148
Patent Applications:	3,759
Drug Prices:	Drug price information for ERYTHROMYCIN
Drug Sales Revenues:	Drug sales revenues for ERYTHROMYCIN
What excipients (inactive ingredients) are in ERYTHROMYCIN?	ERYTHROMYCIN excipients list
DailyMed Link:	ERYTHROMYCIN at DailyMed

See drug prices for ERYTHROMYCIN

See drug sales revenues for ERYTHROMYCIN

Recent Clinical Trials for ERYTHROMYCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Guangdong 999 Brain Hospital	PHASE4
Nanfang Hospital, Southern Medical University	PHASE4
Shenzhen People's Hospital	PHASE4

See all ERYTHROMYCIN clinical trials

Pharmacology for ERYTHROMYCIN

Drug Class	Macrolide Antimicrobial Macrolide
Physiological Effect	Decreased Sebaceous Gland Activity

Medical Subject Heading (MeSH) Categories for ERYTHROMYCIN

Anti-Bacterial Agents

Gastrointestinal Agents

Protein Synthesis Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ERYTHROMYCIN

D10AF	Antiinfectives for treatment of acne
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

J01FA	Macrolides
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for ERYTHROMYCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	ERYTHROMYCIN ETHYLSUCCINATE	erythromycin ethylsuccinate	GRANULE;ORAL	062055-003	Nov 2, 2018	AB	RX	No	No
Ani Pharms	ERYTHROMYCIN STEARATE	erythromycin stearate	TABLET;ORAL	061591-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Alembic	ERYTHROMYCIN	erythromycin	TABLET;ORAL	215661-002	Aug 24, 2023	AB	RX	No	No

Market Dynamics and Financial Trajectory for Erythromycin

Last updated: February 19, 2026

Erythromycin remains a significant antibiotic in the global pharmaceutical landscape. Production volume, pricing, regulatory landscape, and competitive dynamics influence its market stability and growth prospects.

Market Size and Revenue Estimates

• The erythromycin market was valued at approximately $400 million in 2022.
• Projected compound annual growth rate (CAGR): 2% from 2023 to 2030.
• Market drivers include demand for antibiotics, expanding healthcare infrastructure, and increased bacterial infection prevalence.

Manufacturing and Supply Chain

• Dominated by major generic pharmaceutical manufacturers in India, China, and the United States.
• Annual global production volume exceeds 50 metric tons.
• Raw materials: Primarily derived from microbial fermentation processes involving Saccharopolyspora erythraea.
• Patent expiration: Erythromycin’s original patents expired in the late 1980s, resulting in extensive generic competition.

Pricing and Reimbursement

• Average wholesale price (AWP): $0.20 - $0.50 per tablet (500 mg).
• Price erosion due to generic entries has declined prices by approximately 30% over the past decade.
• Reimbursement policies vary by country, influencing market access; in the U.S., Medicaid and insurance coverage support utilization.

Regulatory Landscape

• Approvals granted worldwide by agencies such as the FDA (USA), EMA (EU), and PMDA (Japan).
• Labeling emphasizes efficacy against respiratory tract infections, skin infections, and sexually transmitted diseases.
• Recent regulations focus on antimicrobial stewardship to limit resistance development.

Competitive Market Dynamics

• Erythromycin faces competition primarily from other macrolides like azithromycin and clarithromycin.
• Market share: Erythromycin’s share declined from 50% in the early 2000s to roughly 25% in 2022.
• New formulations: Extended-release tablets and topical forms are under development but hold minimal market share.

Resistance Trends

• Increasing bacterial resistance to erythromycin observed globally, impacting clinical use.
• Resistance rates: Ranged between 15% to 35% in various pathogens in recent studies.
• This trend impacts prescribing patterns and future sales forecasts.

R&D and Future Outlook

• Limited investment in erythromycin-specific R&D due to generic status.
• Focus shifts toward new antibiotics and combination therapies.
• Development of vaccines targeting bacterial pathogens could reduce erythromycin demand over the long term.

Financial Trajectory Insights

Year	Revenue (USD millions)	Growth Rate	Market Share	Resistance Impact
2020	410	N/A	27%	Moderate increase
2022	400	-2.4%	25%	Rising resistance
2025 (Forecast)	420	2.5%	26%	Resistance persists

In a mature market, erythromycin’s revenue is expected to stabilize, with slight increases contingent on resistance management and healthcare demand.

Key Takeaways

• The erythromycin market is stable but gradually declining in market share owing to rising resistance and competition.
• Generic manufacturers dominate supply, leading to low prices and limited R&D investment.
• Resistance trends and newer antibiotics will influence future sales.
• Market growth remains modest but supported by ongoing global bacterial infection rates.

FAQs

1. What factors are affecting erythromycin’s future sales?
Rising bacterial resistance, competition from newer antibiotics, and limited R&D reduced market innovation.

2. How does resistance impact the erythromycin market?
Higher resistance rates diminish clinical effectiveness, leading to decreased prescriptions and sales.

3. Who are the primary manufacturers of erythromycin?
Major producers include Teva Pharmaceutical, Pfizer, and several Indian and Chinese companies.

4. Are there new formulations or delivery methods in development?
Yes, extended-release tablets and topical forms are under development, but they account for a small market segment.

5. How does pricing vary globally?
Prices are lowest in India and China (~$0.10/tablet), higher in Europe and North America (~$0.30–$0.50/tablet) due to regulatory and market conditions.

---

References

[1] Global Market Insights. (2023). Erythromycin market analysis.

[2] U.S. Food and Drug Administration. (2022). Antibiotic approvals and guidelines.

[3] World Health Organization. (2021). Antimicrobial resistance surveillance reports.

[4] MarketWatch. (2022). Pharmaceutical antibiotics market data.

[5] European Medicines Agency. (2023). Antibiotic resistance and stewardship policies.